Knowledge Library
Key Steps in Validating Targeted Protein Degraders
Choose excellence, choose WuXi Biology – your reliable partner in Targeted Protein Degradation (TPD) drug discovery. Since 2016, we have developed comprehensive discovery platforms capable of investigating the complete TPD functional cycle, from binary and ternary complex formation to protein ubiquitination and degradation. Our broad and deep expertise spans diverse TPD modalities, including PROTACs®, molecular …Read More >
OncoWuXi Express: Animal Models of Parkinson’s Disease
Introduction: OncoWuXi Express will continue to keep you informed about updates to our online pharmacology model database (OncoWuXi Database), as well as our recent progress in preclinical research. In this issue, we showcase animal models related to Parkinson’s disease. https://onco.wuxiapptec.com Introduction Pathogenesis of Parkinson’s Disease Parkinson’s Disease (PD) is a widely prevalent neurodegenerative disorder globally. …Read More >
ADC Development: Preclinical Pharmacology Essentials
Antibody-drug conjugates (ADCs) are increasingly demonstrating their value in cancer treatment, especially in combination therapies and for targeting resistant cancer cell populations. The ability of ADCs to deliver highly potent cytotoxic payloads directly to cancer cells that express a target antigen makes them a promising approach for targeted therapy. However, the complex structure and mechanism …Read More >
Targeted Protein Degraders: Trends, Challenges, and Solutions
Since 2016, WuXi AppTec has built a comprehensive discovery platform focused on Targeted Protein Degraders (TPDs). Our platform enables research teams to investigate the complete TPD functional cycle, from binary and ternary complex formation to protein ubiquitination and degradation. Our end-to-end services encompass over 20 assay technologies, 10+ types of TPD molecules, and one-stop screening …Read More >
Innovative R&D Strategies for Peptide Drugs in Obesity Treatment
Introduction: Obesity has emerged as a pressing global public health issue, with its prevalence escalating at an unprecedented rate across the world. Body Mass Index (BMI) is a commonly used indicator to assess the degree of obesity. According to the World Obesity Atlas 2025, by 2030, over 2.9 billion adults globally will have a high …Read More >
Systemic Lupus Erythematosus Animal Models
Systemic lupus erythematosus (SLE) is a serious, chronic autoimmune disorder characterized by a heterogeneous clinical presentation, in which various organs and systems are affected in different ways and with varying degrees of severity. SLE is characterized by an autoimmune reaction involving the innate and adaptive immune systems, including dendritic cells, T cells, and B cells. …Read More >
Endometriosis: Animal Models as Tools to Accelerate New Therapeutics
Introduction Endometriosis is a common gynecological condition that significantly impacts the health of women of reproductive age worldwide. Approximately 10% of reproductive-aged women and girls are affected by this condition [1]. As a complex estrogen-dependent disease, endometriosis can onset from menarche and persist until menopause. There is currently no cure; treatments primarily aim to alleviate …Read More >
Severe Hyperglycemia and Hyperlipidemia Alter Tumor Growth and Immune Profiles in Syngeneic Tumor Models
Studies have demonstrated that obesity can promote cancer progression through mechanisms that include chronic low-grade inflammation. Previous research with diet-induced obese animal models revealed that T cells in colorectal cancer are reduced in obesity. However, it is unclear how the tumor microenvironment changes under severe hyperglycemia and hyperlipidemia in different cancers. At AACR 2025, HD …Read More >
Alterations in Energy Metabolism and Lipogenesis in GIPR/GLP-1R Agonist-Treated MASH Mice
Metabolic Dysfunction-Associated Steatohepatitis (MASH) is a severe form of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). MASH is a growing public health concern due to its increasing prevalence, driven by factors like obesity, type 2 diabetes, and metabolic syndrome. MASH can progress to advanced liver scarring (fibrosis) and cirrhosis, increasing the risk of liver cancer and …Read More >